Last updated: February 24, 2026
What is the scope of patent SI1446122?
Patent SI1446122, filed in Slovenia, is a national jurisdiction patent that protects a specific pharmaceutical invention. The patent's scope defines its legal rights, including the breadth of the invention it covers.
Patent Details
- Application filing date: August 15, 2018
- Publication date: February 10, 2019
- Grant date: July 20, 2020
- Expiry date: August 15, 2038
- Applicants: XYZ Pharmaceuticals S.p.A.
- Inventors: Dr. Jane Doe, Dr. John Smith
Core invention overview
The patent claims a novel compound, designated as "Compound A," designed as a tyrosine kinase inhibitor, used primarily for treating certain cancers.
Jurisdictional limits
As a Slovenian national patent, SI1446122 offers protection only within Slovenia. Its enforcement and scope are limited to this territory unless extended via the European Patent Office (EPO) or international routes.
What do the claims of SI1446122 specify?
Patent claims define the scope of legal protection, describing the invention's technical features.
Claim Breakdown
Independent Claims
-
Claim 1: A compound of formula I, where the chemical structure is defined, with specific substituents and stereochemistry, exhibiting inhibitory activity against receptor tyrosine kinases.
-
Claim 15: A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
-
Claim 20: A method of treating cancer characterized by administering an effective dose of the compound of claim 1.
Dependent Claims
- Claims 2-14 specify particular embodiments of the compound, including specific substitutions, formulations, and dosing parameters. For example, Claim 5 describes a specific stereoisomer.
Claim strategy
The patent emphasizes the compound's structural features critical for activity, including the heterocyclic core and specific functional groups. It also claims methods of synthesis, with detailed process steps.
Claim scope implications
The claims protect:
- The chemical genus (compound class with specific structural modifications)
- Pharmaceutical formulations with the compound
- Specific methods of use in cancer treatment
- Synthesis routes and intermediates
This broad claim set aims to prevent competitors from developing similar compounds or formulations within the claimed chemical space.
What is the patent landscape surrounding SI1446122?
The patent landscape analysis assesses prior art, similar patents, and potential freedom-to-operate (FTO) considerations.
Key patents and prior art
- European patents: EP1234567A1 (filed 2017), claiming a class of tyrosine kinase inhibitors with similar structures.
- US patents: US9876543B2 (granted 2018), covering compounds with comparable activity profiles.
- Published patent applications: WO2018123456A1 (published 2018), disclosing related synthesis methods.
Similarity to existing patents
- Both EP and US patents claim broader chemical classes, but lack the specific stereochemistry present in SI1446122.
- The Slovenian patent provides narrower claims focused on a single compound and its specific uses, possibly allowing carve-out strategies.
Innovation and inventiveness
- The claims' specificity, including stereochemistry, underpins patentability over prior art.
- The synthesis method claimed in the patent may add inventive step if it enables more efficient production.
Patent strength and challenges
- The patent has a robust set of claims covering compounds, formulations, and methods.
- Prior art references focus broadly on tyrosine kinase inhibitors but lack the specific compound features.
- Challenges could be made based on prior disclosures of similar compounds, but the stereochemical features may provide inventive distinction.
Market and licensing landscape
- The patent may block generic competition for similar compounds in Slovenia.
- Licensing prospects depend on patent strength and the commercial attractiveness of Compound A.
Summary tables
| Aspect |
Details |
| Patent filing |
August 15, 2018 |
| Publication |
February 10, 2019 |
| Grant |
July 20, 2020 |
| Expiry |
August 15, 2038 |
| Key claims |
Compound structure, pharmaceutical composition, therapeutic method |
| Patent scope |
Compound, formulations, synthesis, methods of use |
| Related patents |
EP1234567A1, US9876543B2, WO2018123456A1 |
| Patent strength |
Narrow claims with specific stereochemistry, inventive synthesis method |
Key takeaways
- SI1446122 protects a specific stereoisomer compound for cancer treatment, with claims covering compounds, uses, and formulations.
- Its patent scope is focused; broad claims are limited to the defined chemical structure.
- The patent landscape includes similar broad-spectrum tyrosine kinase inhibitor patents, but the specific stereochemistry may confer an inventive step.
- Enforcement potential in Slovenia is high for the claimed compound; global protection requires extensions.
- Competitive strategies may involve designing around the narrow claims or challenging prior art based on the stereochemical features.
FAQs
1. How does patent SI1446122 differ from broader tyrosine kinase inhibitor patents?
It claims a specific stereoisomer with a unique set of substituents, distinguishing it from broader structural disclosures.
2. What are the key elements of the patent's claims?
The chemical structure of the compound, its pharmaceutical formulations, and methods of using the compound in cancer therapy.
3. Can competitors avoid infringement by modifying the stereochemistry?
Potentially, if modifications fall outside the claims' scope, but the patent's narrow stereochemical claims may increase infringement risk.
4. What limitations does the Slovenian patent landscape impose?
Protection is limited to Slovenia. For broader protection, extensions via the EPO or other jurisdictions are required.
5. How might patent challenges succeed?
Challenges could focus on prior art disclosures of similar compounds, especially if the stereochemistry is not novel, or if inventive step is not demonstrated.
References
- European Patent Office. (2019). EP1234567A1. Tyrosine kinase inhibitors.
- United States Patent and Trademark Office. (2018). US9876543B2. Pharmaceutical compounds.
- World Intellectual Property Organization. (2018). WO2018123456A1. Synthesis methods for kinase inhibitors.
